ISRCTN11439124已完成不适用
G-Protein Coupled Purinergic Receptor P2Y2 (P2RY2) gene rs4944832 polymorphism increases the risk of ischemic stroke in the northern Han Chinese population
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 722
研究概览
简要总结
2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/30539820
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •Inclusion criteria for the ischemic stroke group:
- •1. According to the TOAST classification, patients in the ischemic stroke group were diagnosed depending on clinical features and neuroimaging criteria that included the sudden onset of a global or focal neurological deficit, with corresponding brain infarction as seen on computed tomography (CT) imaging or magnetic resonance imaging (MRI) (Adams et al., 1993). Examinations of cerebral blood vessels, such as computed tomography angiography and magnetic resonance angiography, were performed when necessary.
- •Inclusion criteria for the control group:
- •1. Unrelated healthy controls with no clinical or radiological evidence of stroke or cerebrovascular diseases.
- •2. Some healthy controls had vascular risk factors such as hypertension, diabetes, smoking, drinking, and hypercholesterolemia.
排除标准
- •Exclusion criteria for the ischemic stroke group:
- •2. Hemorrhagic stroke
- •3. Transient ischemic attack
- •4. Severe cardiac, hepatic, or renal diseases
- •Exclusion criteria for control subjects:
- •2. Autoimmune disease
- •3. Chronic inflammation
- •4. Renal insufficiency
- •5. Liver insufficiency
- •6. Hematopathy
研究者
相似试验
进行中(未招募)
2 期
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 DiabetesType 2 Diabetes Mellitus (T2DM)Obesity Type 2 Diabetes MellitusNCT06712615ProGen. Co., Ltd.144
已完成
2 期
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate CancerStage II Prostate AdenocarcinomaStage III Prostate AdenocarcinomaStage IV Prostate AdenocarcinomaNCT03113617Andrei Iagaru44
终止
2 期
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine TumorsGastro-entero-pancreatic Neuroendocrine TumorsNCT02736448Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori35
已完成
2 期
Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk VariantType 2 DiabetesNCT01593215Anders Rosengren, MD PhD50
撤回
2 期
A Trial Of PF-04856884 In Patients With Recurrent GlioblastomaGlioblastomaNCT01225510Pfizer
